ClinicalTrials.gg
RecruitingNCT07081919Updated Jul 23, 2025

Effectiveness, Stability and Influence Factors of Femtosecond Laser Assisted Cataract Surgery

An observational study in Corneal Astigmatism and Cataract, sponsored by Eye & ENT Hospital of Fudan University. Recruiting at 1 site in China. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-07-23.

Sponsored by Eye & ENT Hospital of Fudan University · Observational

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
105
Ages
20 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Astigmatism with a site in China — 11 open to participants now, 13 under way, none of them phase 3. Astigmatism · China.

Planned enrollment
9th of 12
105 · median 492
Started
2025
with 3 others
Observational
12 of 29
5 open now
Primary completion
2030-04
later than 11 of 12 live
Registered
22nd of 29
by date
Lead sponsor
2 of 29
Eye & ENT Hospital of Fudan University

Among the 29 studies in Astigmatism with a site in China, this one is the 9th largest by planned enrollment of the 12 observational ones that give a count, is one of 4 that started in 2025, is one of 12 observational ones, reaches primary completion later than 11 of the 12 other live ones, and was the 22nd registered.

Astigmatism

418 studies on the registry are indexed under Astigmatism; 51 are open to participants now.

Browse Astigmatism studies →

Open to participants now

11 of the 29 studies in Astigmatism with a site in China are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 32 Astigmatism studies recruiting now, 12 (38%) set no upper age limit and 15 (47%) stop at 75 or younger; 5 take children under 18; 10 take healthy volunteers.

This study: 20 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Astigmatism with a site in China, or all of them as a file.
02

Study summary

What is this study about? This study looks at whether a laser procedure called femtosecond laser-assisted arcuate keratotomy (FSAK) helps people with both cataracts and mild astigmatism see more clearly after cataract surgery. Astigmatism causes blurry vision because the front of the eye (cornea) is curved unevenly. The FSAK procedure uses a computer-guided laser to make tiny, precise cuts in the cornea during cataract surgery to fix this curve. the investigators want to see if this improves vision long-term (up to 5 years) and what factors affect how the investigatorsll it works.

Who can join? the investigators are looking for adults aged 20-80 years who:

Have cataracts and mild-to-moderate astigmatism (0.75-2.0 diopters) Plan to have cataract surgery Have not had prior eye surgeries (like LASIK) Do not have severe dry eye or other eye diseases (like glaucoma or retina problems) What will happen in the study?

Surgery: Participants will have cataract surgery combined with the FSAK procedure. The surgeon uses a laser to make tiny curved cuts in the cornea to reshape it.

Follow-up visits: Participants will have regular eye check-ups for 5 years after surgery. These include:

Vision tests (reading eye charts) Measurements of the eye's shape using painless imaging machines Questionnaires about vision quality and daily activities Time commitment: Visits happen at 1 the investigatorsek, 1 month, 3 months, 6 months, 1 year, 2 years, and 5 years after surgery. Each visit takes about 1-2 hours.

Why is this study important? FSAK may help people with astigmatism see clearly after cataract surgery without needing glasses as often. By tracking results for 5 years, the investigators'll learn how long the benefits last and who benefits most. This could help doctors better personalize treatment in the future.

Who is running the study? Eye doctors at Fudan University Eye \& ENT Hospital (Shanghai) and Shanghai Peace Eye Hospital. About 105 people will take part.

Read the detailed description

Study Description for General Audience

What's the problem? Many people with cataracts also have an irregularly curved front surface of the eye (called astigmatism). After cataract surgery, this astigmatism can still cause blurry or distorted vision, making everyday tasks like reading or driving difficult. While glasses or special lenses can help, many hope to reduce their dependence on them after surgery.

What's being tested?

This study evaluates a laser procedure called Femtosecond Laser-Assisted Arcuate Keratotomy (FSAK). During cataract surgery:

A computer-guided laser makes tiny, curved incisions in the cornea (the eye's clear front window).

These precise incisions gently reshape the cornea to improve its natural curve. Think of it like a sculptor smoothing uneven surfaces-but using light-speed technology.

Why is this study unique?

While FSAK isn't brand new, the investigators lack long-term data on:

How the investigatorsll it holds up over 5+ years. Which factors predict success (e.g., does participantsr eye's shape or pressure affect results?).

the investigators're following participants for 5 years to ansthe investigatorsr these questions-far longer than most existing studies.

What will participants experience?

Surgery: FSAK is combined with standard cataract removal. The laser step adds only minutes.

Follow-ups: Painless check-ups at 1 the investigatorsek, 1 month, 3 months, 6 months, 1 year, 2 years, and 5 years after surgery. These involve:

Reading eye charts. Quick scans to map the eye's surface. Short questionnaires about vision quality (e.g., glare at night or reading small print).

Why does this matter?

If successful, FSAK could:

  • Help people see clearly longer after cataract surgery.
  • Reduce the need for glasses or contacts.
  • Give doctors better tools to personalize treatment.

Who's involved?

Led by eye specialists at Fudan University Eye \& ENT Hospital and Shanghai Peace Eye Hospital.

03

Conditions studied

  • Corneal Astigmatism
  • Cataract

Keywords

  • femtosecond laser-assisted arcuate keratotomy
  • cataract surgery
  • corneal astigmtism
  • astigmatism treatment stability
  • predictors of surgical outcomes
04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with regular corneal astigmatism of 0.75-2.0 D who plan to undergo cataract surgery.

Aged between 20 and 80 years old.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: 20-80 years
  • Age-related cataracts
  • Regular corneal astigmatism (0.75-2.0 diopters) confirmed by Pentacam/IOLMaster 700
  • Surgical Plan: Scheduled for femtosecond laser-assisted cataract surgery
  • Central corneal thickness ≥500 µm
  • Endothelial cell count ≥2,000 cells/mm²
  • Best-corrected visual acuity (BCVA) improvable to ≥20/40

Exclusion criteria

Exclusion Criteria

  • Prior corneal refractive surgery (e.g., LASIK, PRK)
  • Intraocular surgery (e.g., glaucoma filtering surgery)
  • Irregular astigmatism (keratoconus, scarring, post-traumatic distortion)
  • Active ocular inflammation or infection
  • Corneal endothelial disease (e.g., Fuchs' dystrophy)
  • Severe dry eye (Schirmer test ≤5 mm/5 min)
  • Uncontrolled glaucoma (IOP >21 mmHg on medication)
  • Macular pathology (e.g., AMD, DME affecting visual potential)
  • Amblyopia
  • diseases affecting cornea (e.g., rheumatoid arthritis, Sjögren syndrome)
  • Diabetes mellitus with retinopathy
  • Pregnancy/Lactation
  • Inability to complete 5-year follow-up
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
105 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • FSAK with Cataract Surgery

    Participants in this group undergo femtosecond laser-assisted arcuate keratotomy (FSAK) combined with standard cataract surgery

    Procedure: femtosecond laser-assisted arcuate keratotomy (FSAK) combined with standard cataract surgery

Interventions

  • Procedurefemtosecond laser-assisted arcuate keratotomy (FSAK) combined with standard cataract surgery

    1. 5-year follow-up assessing stability of astigmatism correction. Most FSAK studies track ≤2 years. This addresses critical evidence gaps in durability 2. Combines topographic data with patient-reported visual function (VF-14/QoV questionnaires at all visits. Links anatomical changes to real-world visual experiences

06

What researchers measure

Primary outcomes

  1. Change in corneal astigmatism magnitude (diopters) from baseline

    Time frame: Preoperative; 1 week postoperatively, 1 month postoperatively, 3 months postoperatively, 6 months postoperatively, 1 year postoperatively, 2 years postoperatively, 5 years postoperatively

Secondary outcomes

  1. Visual Acuity-UCVA

    Uncorrected Distance Visual Acuity (UDVA) at 5m (logMAR)

    Time frame: Preoperative; 1 week postoperatively, 1 month postoperatively, 3 months postoperatively, 6 months postoperatively, 1 year postoperatively, 2 years postoperatively, 5 years postoperatively

  2. Visual acuity-BCVA

    Best-Corrected Visual Acuity (BCVA) at 5m (logMAR)

    Time frame: Preoperative; 1 week postoperatively, 1 month postoperatively, 3 months postoperatively, 6 months postoperatively, 1 year postoperatively, 2 years postoperatively, 5 years postoperatively

  3. Manifest refraction spherical equivalent (MRSE) in Diopter (D)

    Time frame: Preoperative; 1 week postoperatively, 1 month postoperatively, 3 months postoperatively, 6 months postoperatively, 1 year postoperatively, 2 years postoperatively, 5 years postoperatively

  4. Corneal Topography

    Corneal Topography assesses corneal curvature, with data collected using the Pentacam instrument and IOL Master. The measured outcome reflects the corneal's refractive power and shape characteristics. Corneal curvature is reported in diopters (D) , a standard unit for quantifying refractive power in ophthalmic measurements.

    Time frame: Preoperative; 1 week postoperatively, 1 month postoperatively, 3 months postoperatively, 6 months postoperatively, 1 year postoperatively, 2 years postoperatively, 5 years postoperatively

  5. Objective Optical Quality

    Objective visual quality is evaluated by measuring Total ocular higher - order aberrations (HOAs, unit: µm) and Strehl ratio (SR) using the iTrace instrument. Total ocular higher - order aberrations reflect the deviation of the eye's optical system from an ideal state, where higher values generally indicate greater optical imperfections that may disrupt visual clarity. The Strehl ratio, on the other hand, quantifies the quality of optical imaging; a higher SR (ranging from 0 to 1, with 1 representing ideal optical quality) signifies better visual quality, as it relates to the concentration of light in the retinal image. These metrics, derived from iTrace measurements, provide objective assessments of how well the eye processes visual input, crucial for evaluating surgical outcomes (e.g., cataract or refractive surgery) and ocular health.

    Time frame: Preoperative; 1 week postoperatively, 1 month postoperatively, 3 months postoperatively, 6 months postoperatively, 1 year postoperatively, 2 years postoperatively, 5 years postoperatively

  6. Patient-Reported Outcomes

    bjective visual quality can be assessed with the Visual Function-14 (VF-14) questionnaire, which evaluates 14 vision-dependent daily activities. Patients self-rate their functional limitations, with scores ranging from 0 (worst) to 100 (best), where higher scores indicate better visual function. It is administered preoperatively and 3 months postoperatively to measure changes, with a minimal clinically important difference of 15.57, meaning a score change exceeding this value signifies a meaningful improvement The DOI of reference for visual function questionnaire is 10.1016/j.ophtha.2010.04.009.

    Time frame: Preoperative; 1 week postoperatively, 1 month postoperatively, 3 months postoperatively, 6 months postoperatively, 1 year postoperatively, 2 years postoperatively, 5 years postoperatively

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Data contain sensitive biometric identifiers (e.g., corneal topography maps) that cannot be fully de-identified

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Apr 2030, 60 months after the start.

Of 35 observational studies under Astigmatism, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 92. This study's planned 60 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2025
First posted
Jul 23, 2025
StartActual
Apr 22, 2025
Primary completionEst.
Apr 22, 2030
CompletionEst.
Apr 22, 2031
Last update
Jul 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07081919
Responsible party
Jin Yang (Chief Physician, Eye & ENT Hospital of Fudan University) — Principal investigator
First posted
Jul 23, 2025
Start date
Apr 22, 2025
Primary completion
Apr 22, 2030 (estimated)
Completion
Apr 22, 2031 (estimated)
Last update
Jul 23, 2025

Study contacts

Jin Yang, PhD
Contact
jin_er76@hotmail.com
13671632525

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion